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Abstract
In this randomized, multicenter trial, we evaluated the effectiveness and side
effect profile of a modified omeprazole-based triple therapy to cure Helico-
bacter pylori infection. The control group consisted of patients treated with
standard dual therapy comprising omeprazole and amoxicillin. One hundred
and fifty-seven H. pylori infected patients with duodenal ulcers were randomly
assigned to receive either a combination of omeprazole 10 mg, clarithromycin
250 mg and metronidazole 400 mg (OCM) given three times daily for 10 days
(n = 81), or a combination of omeprazole 20 mg and amoxicillin 1 g (OA)
given twice daily for 14 days (n = 76). Prior to treatment and after 2 and
6 weeks, gastric biopsies from the antrum and corpus were obtained for histol-
ogy and H. pylori culture. H. pylori infection was cured in 97.4% after OCM
and in 65.8% after OA in the per-protocol analysis (p ! 0.001) (intention-
to-treat analysis: 93.4% and 63.2%, respectively). H. pylori was successfully
cultured in 122 patients (77%). The overall rate of metronidazole resistance
was 19.7% (24/122), no primary resistance to clarithromycin or amoxicillin
was found. In the OCM group, all patients infected with metronidazole-sensi-
tive H. pylori strains (n = 51) and those infected with strains of unknown
susceptibility to metronidazole (n = 14) were cured (100%), while 77% (10/13)
of those harboring metronidazole-resistant strains were cured of the infection
(p = 0.36). Side effects leading to premature termination of treatment occurred
in 2.5% of the patients in the OCM group and in 1.4% of the OA group. We
conclude that combined treatment with omeprazole, clarithromycin and a
higher dose of metronidazole is highly effective in curing H. pylori infection,
and that this regimen remains very effective in the presence of metronidazole-
resistant strains.
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Introduction
It is well recognized that Helicobacter pylori is the prin-
cipal cause of chronic gastritis and duodenal ulcer disease
[1]. In 1994, the National Institute of Health Consensus
Development Conferences on H. pylori in peptic ulcer
disease recommended antimicrobial therapy for ulcer pa-
tients whether on the first presentation of illness or on
recurrence [2]. However, in routine practice, cure of the
infection has proven to be difficult. Complex regimens
such as the combination of bismuth salts, metronidazole
and tetracycline although highly effective are limited by
poor patient compliance or antimicrobial resistance to
nitroimidazoles [3]. Dual therapy comprising omeprazole
and amoxicillin (OA) is simple, well tolerated, and cures
H. pylori infection in up to 90% depending on the daily
dose of omeprazole [4, 5], however, variable cure rates
have been reported [6–8]. Omeprazole-based triple-thera-
py regimens consistently cure H. pylori infection in 90%
and more [9–12], however, few data exist about the effica-
cy of such a regimen in the presence of metronidazole-
resistant H. pylori strains. In this randomized study, we
evaluated the effectiveness and tolerability of combined
treatment with omeprazole, clarithromycin and metroni-
dazole (OCM) each given three times daily in comparison
with standard dual therapy comprising omeprazole 20 mg
b.i.d. and amoxicillin 1 g b.i.d. In addition, pre- and post-
treatment resistance to the antibiotics in use was deter-
mined.
Methods
Study Population
Patients aged 18–80 years with H. pylori-associated duodenal
ulcers were included in this randomized, multicenter study. Exclu-
sion criteria were an additional gastric or pyloric ulcer, use of bis-
muth compounds or antibiotics 4 weeks prior to endoscopy, regular
consumption of steroids, NSAIDs or more than 100 mg of acetylsali-
cylic acid per day, previous ulcer surgery, pregnancy, renal insuffi-
ciency, known allergy to those antibiotics used and contraindications
of biopsy.
Therapy
Patients were randomly treated with either a combination of
omeprazole 10 mg, clarithromycin 250 mg and metronidazole
400 mg (OCM) given three times daily with meals for 10 days, or
standard dual therapy comprising omeprazole 20 mg and amoxicillin
1 g (OA) given twice daily with meals for 14 days. The latter regimen
was the only approved anti-H. pylori therapy in 1993 when the
present study was planned. Drug compliance was assessed by pill
count and a diary where patients recorded adverse events.
Endoscopy and Histology
Endoscopic examinations were conducted prior to treatment,
after 2 weeks to document ulcer healing and after 6 weeks to deter-
mine cure of H. pylori infection. At each endoscopy, 4 biopsy speci-
mens from the antrum and 2 from the corpus were obtained for histo-
logic examination, a number considered to ensure reliable detection
of H. pylori [13]. Biopsy specimens were placed in neutral buffered
formalin. HE staining was performed to grade gastritis, and Warthin-
Starry staining to detect and grade mucosal H. pylori colonization
according to the Sydney System [14]. Patients who were H. pylori-
negative at histology and culture prior to treatment were withdrawn
and treated conventionally.
H. pylori Culture and Susceptibility Testing
Two antral biopsy specimens were taken for microbiological
examinations. Culture biopsies were transported to the Department
of Microbiology, in Portagerm pylori transport medium (BioMé-
rieux, Marcy-l’Etoile, France) within 24 h. Immediately after arrival,
H. pylori was cultured on Pylori agar (BioMérieux) and Wilkins-
Chalgren agar medium supplemented with 10% horse blood and
Skirrow Antibiotic Supplement (Oxoid, Basingstoke, UK). H. pylori
was identified by typical gram stain morphology, and by biochemical
tests positive for oxidase, catalase and urease. For susceptibility test-
ing, cells were harvested from a 2- to 3-day fresh culture on Wilkins-
Chalgren agar and transferred to 1 ml of brucella broth (Difco, Augs-
burg, Germany). Inoculum density was adjusted to McFarland 3–4
which represents approximately 0.5 ! 109 colony-forming units
(CFU)/ml. Motility and morphology were checked by phase contrast
microscopy. The suspension was discarded if more than one fourth of
rounded organisms or clumped aggregates were detected. A Wilkins-
Chalgren agar plate was flooded and allowed to dry for 5–10 min.
One E-test strip (AB Biodisk, Solna, Sweden) was placed on the agar,
and the plate was incubated under microaerophilic conditions (11%
O2, 9% CO2, 80% N2) for 2–3 days until sufficient growth was visible.
The results were read according to the manufacturer’s instructions.
Interpretation criteria for clarithromycin were sensitive for MIC val-
ues ^0.125 mg/l and resistant for 62 mg/l. The corresponding val-
ues for metronidazole were 8 and 32 mg/l, and for amoxicillin 2 and
4 mg/l, respectively.
Definition of H. pylori Status
At baseline examination, patients were considered H. pylori-
infected when either histology or culture was positive. Cure of H.
pylori infection was assessed at least 4 weeks after completion of
treatment, and was defined as being H. pylori-negative on histology
and culture.
Statistical calculations were performed using the statistical soft-
ware package SPSS/PC+5.0 (SPSS Inc., USA). Rate comparisons
were made with the ¯2 test. The study was approved by the Ethics
Committee of the University of Munich.
Results
One-hundred fifty-seven DU patients infected with H.
pylori were randomized to one of the two treatment
groups, 81 to the OCM group, and 76 to the OA group.
The overall study population consisted of 101 men and 56
Mean age, years
Ulcer healing
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Table 1. Characteristics of study patients
OCM OA p
47.8B15.1 50.7B14.8 0.53
Male/female 56/25 45/31 0.19
Consumption of
Alcohol 58 48 0.37
Coffee 59 54 0.45
Smoking 43 38 0.57
Table 2. Ulcer healing and H. pylori cure rates following treat-
ment with OCM in patients infected with metronidazole-sensitive or
metronidazole-resistant H. pylori strains and following treatment
with OA
OCM OA
overall 81/81 (100) 74/76 (97.3)
H. pylori cure
Per protocol 76/78 (97.4) 48/73 (65.8)
Intention-to-treat 76/81 (93.4) 48/76 (63.2)
MET-sensitive 51/51 (100)
MET-resistant 10/13 (77)
Unknown susceptibility 14/14 (100)
Figures in parentheses are percentages. MET = Metronidazole.
women (age range 26–78 years, mean age 49.6 years).
There was no statistically significant difference in the
patient characteristics between the OCM and the OA
group (table 1). One patient of the OCM group (1.2%) was
lost to follow-up. Side effects leading to premature termi-
nation of treatment occurred in 2 of 81 patients (2.5%) in
the OCM group (diarrhea), and in 1 of 74 patients (1.4%)
in the OA group (p 1 0.5) (allergic skin reaction). In all
cases, the side effects were self-limiting after termination
of treatment. These 4 patients were therefore excluded
from the per-protocol analysis. Minor adverse events were
observed in 13 patients (16.7%) and in 9 patients (11.8%)
in the respective treatment groups (p 1 0.5), mainly mild
diarrhea, taste disturbance, mild nausea, headache.
Ulcer healing determined 2 weeks after initiation of
treatment was achieved in 81/81 patients in the OCM
group, and in 74/76 (97.3%) of the patients in the OA
group. The 2 patients without documented ulcer healing
were also excluded from the per-protocol analysis. Cure of
H. pylori infection was documented in 97.4% of patients
(76/78) following treatment with OCM (intention-to-treat
analysis 93.4%; 76/81) and in 65.8% of patients (48/73)
after OA therapy (intention-to-treat analysis 63.2%; 48/
76) (p ! 0.001). In 122 of 157 patients, culture for H. pylo-
ri was successful (77%). Twenty-four of the available 122
pretreatment H. pylori isolates (19.7%) were resistant to
metronidazole (13/64 in the OCM group, and 11/58 in the
OA group). In the OCM group, all patients infected with
metronidazole-sensitive H. pylori strains (n = 51) and
those infected with strains of unknown susceptibility to
metronidazole (n = 14) were cured (100%), while 77%
(10/13) of those harboring metronidazole-resistant strains
were cured of the infection (p = 0.36). In the OA group, 8
of 11 (73%) patients infected with metronidazole-resis-
tant strains were cured of the infection. None of the pre-
and posttreatment isolates were resistant to clarithromy-
cin or amoxicillin (table 2).
Discussion
Although H. pylori is sensitive to a number of antimi-
crobials and anti-ulcer agents in vitro, curing the infection
in vivo has proven to be a difficult task. Multi-drug regi-
mens are generally required to achieve consistent high
cure rates. In 1993, Bazzoli et al. [9] introduced a simple
and highly effective treatment strategy combining ome-
prazole with two antibiotics given for 1 week. Subsequent
trials using different combinations of antimicrobials were
able to confirm those data [10–12]. In the present study,
we demonstrated a high efficacy of more than 95% in cur-
ing H. pylori infection with a modified omeprazole-based
triple therapy comprising clarithromycin and metronida-
zole given three times instead of twice daily for 10 days.
This finding is in agreement with recently reported stud-
ies using standard-dose triple-therapy regimens [15, 16].
A well-recognized problem of various anti-H. pylori
therapy regimens is primary resistance of H. pylori against
metronidazole ranging from 11 to 25% in Western coun-
tries [17–19], and even up to 95% in developing countries
[20]. While resistance of H. pylori against metronidazole
has been shown to be a fundamental problem for the origi-
nal standard triple therapy comprising bismuth, tetracy-
cline and metronidazole [3], the effectiveness of the new
omeprazole-based triple-therapy regimens in curing infec-
tion with metronidazole-resistant H. pylori isolates has
not been investigated thoroughly. In the present study, the
overall frequency of metronidazole resistance was close to
20%. However, in the 13 patients of the OCM group who
Modified Omeprazole-Based Triple
Therapy
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harbored metronidazole-resistant H. pylori isolates, 10
(77%) were cured of the infection suggesting that even in
the presence of metronidazole resistance this regimen is
still effective, either due to the higher daily dose of
metronidazole (3 ! 400 mg) or to the extended length of
treatment. More strikingly, all other patients in the OCM
group (100%) who were infected with metronidazole-sen-
sitive strains or strains with unknown susceptibility were
cured, underlining the excellent efficacy of this regimen.
Clarithromycin is one of the most active compounds
(MIC90 1 0.03 g/ml) among the various antimicrobials
and anti-ulcer agents that have been tested in vitro against
H. pylori [21, 22]. When used as monotherapy, clarithro-
mycin has the ability to cure H. pylori infection in up to
54% of patients [23]. Today, clarithromycin is an essen-
tial compound of triple-therapy regimens comprising om-
eprazole and metronidazole or amoxicillin [24]. Reported
resistance rates of H. pylori against clarithromycin range
from 0 to 12% [15, 24–26]. In our study, primary or
acquired resistance of H. pylori against clarithromycin
did not occur, again indicating the high suitability of this
antimicrobial for anti-H. pylori combination regimens.
Dual therapy with OA has initially shown promising
results in curing H. pylori infection, in particular when
higher daily doses of omeprazole have been used [4, 5,
27]. However, other investigators failed to reproduce
these data [6–8], and subsequent studies revealed that this
regimen may be sensitive to various, mostly patient-relat-
ed factors. It has been shown that lack of compliance,
short duration of therapy, smoking and pretreatment with
omeprazole are independent factors with a negative in-
fluence on treatment success, while older age of patients,
high-grade gastritis and gastric ulcer are predictors for a
higher success rate [28]. In this study, the control group
was treated with the standard dosage of omeprazole,
20 mg b.i.d. and amoxicillin 1 g b.i.d., since this regimen
was the only approved therapy for treatment of H. pylori-
associated ulcers in 1993 when the present study was
planned. We observed a 66% cure rate of H. pylori infec-
tion, which is basically in agreement with our own pre-
vious data [27] and a recent meta-analysis by van der
Hulst et al. [29]. Based on 53 treatment arms, including a
total of 2,275 patients using omeprazole given twice daily
in combination with amoxicillin for 2 weeks, they found a
mean eradication rate of 62%. These findings certainly do
not justify the use of this regimen as a first-line treatment,
however, dual therapy regimens comprising high-dose
omeprazole (e.g., 120 mg/day) might be useful in the
future when antimicrobial resistance of H. pylori may
become a considerable problem.
Another important finding in this study was the excel-
lent rate of ulcer healing determined 2 weeks after initia-
tion of therapy in both treatment arms (OCM 100%, OA
97.3%). These findings are basically in agreement with a
recently published randomized double-blind study by La-
benz et al. [30] showing that continuation of antisecretory
drug therapy beyond anti-H. pylori therapy may be unnec-
essary to achieve rapid symptom relief and reliable heal-
ing of uncomplicated duodenal ulcers. In conclusion,
combined treatment with OMC for the cure of H. pylori
infection in duodenal ulcer patients is significantly more
effective than standard dual therapy with OA. Even in the
presence of metronidazole-resistant H. pylori isolates is
this modified omeprazole-based triple-therapy regimen
very effective, most likely due to the higher daily dose of
metronidazole.
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